Meridian Bioscience - VIVO Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Meridian Bioscience in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" VIVO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VIVO, but not buy additional shares or sell existing shares.
View VIVO analyst ratings or view top-rated stocks.

2 brokers have issued 1 year price targets for Meridian Bioscience's shares. Their VIVO share price forecasts range from $34.00 to $34.00. On average, they anticipate the company's share price to reach $34.00 in the next twelve months. This suggests a possible upside of 0.1% from the stock's current price.
View analysts price targets for VIVO or view top-rated stocks among Wall Street analysts.

Meridian Bioscience, Inc. (NASDAQ:VIVO) issued its quarterly earnings data on Friday, November, 12th. The company reported $0.24 EPS for the quarter, topping analysts' consensus estimates of $0.21 by $0.03. The firm had revenue of $76.20 million for the quarter, compared to analysts' expectations of $68.40 million. Meridian Bioscience had a net margin of 12.70% and a trailing twelve-month return on equity of 16.74%. During the same quarter in the previous year, the firm posted $0.19 earnings per share.

ETFs with the largest weight of Meridian Bioscience (NASDAQ:VIVO) stock in their portfolio include AltShares Event-Driven ET (EVNT) and AltShares Merger Arbitrage ETF (ARB).WisdomTree U.S. SmallCap Fund (EES).

7 employees have rated Meridian Bioscience Chief Executive Officer Jack Kenny on Glassdoor.com. Jack Kenny has an approval rating of 56% among the company's employees. This puts Jack Kenny in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Meridian Bioscience investors own include AbbVie (ABBV), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Pfizer (PFE), AT&T (T), Gilead Sciences (GILD), Amgen (AMGN), Alibaba Group (BABA) and Tesla (TSLA).

Meridian Bioscience trades on the NASDAQ under the ticker symbol "VIVO."

Meridian Bioscience's stock is owned by a variety of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (4.77%), Dimensional Fund Advisors LP (4.07%), Alliancebernstein L.P. (2.98%), Geode Capital Management LLC (2.00%), AQR Arbitrage LLC (1.83%) and Morgan Stanley (1.47%). Insiders that own company stock include Andrew S Kitzmiller, Anthony P Bihl III, Bryan T Baldasare, John Mccune Jr Rice, John P Kenny and Lourdes Weltzien.
View institutional ownership trends.

One share of VIVO stock can currently be purchased for approximately $33.97.

Meridian Bioscience (NASDAQ:VIVO) has a market capitalization of $1.50 billion and generates $333.02 million in revenue each year. The company earns $42.46 million in net income (profit) each year or $0.97 on an earnings per share basis.

The company employs 702 workers across the globe.

Meridian Bioscience's mailing address is 3471 RIVER HILLS DRIVE, CINCINNATI OH, 45244. The official website for the company is www.meridianbioscience.com. The company can be reached via phone at (513) 271-3700, via email at mbi@meridianbioscience.com, or via fax at 513-271-3762.